Skip to main navigation Skip to search Skip to main content

Methylphenidate and Sleep Difficulties in Children and Adolescents With ADHD: Results From the 2-Year Naturalistic Pharmacovigilance ADDUCE Study

  • Alexander Häge
  • , Kenneth K.C. Man
  • , Sarah K. Inglis
  • , Jan Buitelaar
  • , Sara Carucci
  • , Marina Danckaerts
  • , Ralf W. Dittmann
  • , Bruno Falissard
  • , Peter Garas
  • , Chris Hollis
  • , Kerstin Konrad
  • , Hanna Kovshoff
  • , Elizabeth Liddle
  • , Suzanne McCarthy
  • , Antje Neubert
  • , Peter Nagy
  • , Eric Rosenthal
  • , Edmund J.S. Sonuga-Barke
  • , Alessandro Zuddas
  • , Ian C.K. Wong
  • David Coghill, Tobias Banaschewski*
*Corresponding author for this work
    • Universitat Heidelberg
    • University College London
    • University College London Hospitals NHS Foundation Trust
    • University of Hong Kong
    • University of Dundee
    • Donders Institute for Brain, Cognition and Behaviour
    • Karakter Child and Adolescent Psychiatry University Centre
    • Università degli Studi di Cagliari
    • University Hospital Leuven
    • Paris Saclay University
    • Semmelweis Egyetem
    • University of Nottingham
    • Aachen University Hospital
    • Rheinisch-Westfälische Technische Hochschule Aachen
    • University of Southampton
    • University College Cork
    • Universitätsklinikum Erlangen
    • Bethesda Children’s Hospital
    • Evelina London Children's Healthcare
    • King's College London
    • University of Melbourne

    Research output: Contribution to journal › Article › peer-review

    Abstract

    Objective: Short-term RCTs have demonstrated that MPH-treatment significantly reduces ADHD-symptoms, but is also associated with adverse events, including sleep problems. However, data on long-term effects of MPH on sleep remain limited. Methods: We performed a 2-year naturalistic prospective pharmacovigilance multicentre study. Participants were recruited into three groups: ADHD patients intending to start MPH-treatment (MPH-group), those not intending to use ADHD-medication (no-MPH-group), and a non-ADHD control-group. Sleep problems were assessed with the Children’s-Sleep-Habits-Questionnaire (CSHQ). Results: 1,410 participants were enrolled. Baseline mean CSHQ-total-sleep-scores could be considered clinically significant for the MPH-group and the no-MPH-group, but not for controls. The only group to show a significant increase in any aspect of sleep from baseline to 24-months was the control-group. Comparing the MPH- to the no-MPH-group no differences in total-sleep-score changes were found. Conclusion: Our findings support that sleep-problems are common in ADHD, but don’t suggest significant negative long-term effects of MPH on sleep.

    Original languageEnglish
    Pages (from-to)699-707
    Number of pages9
    JournalJournal of Attention Disorders
    Volume28
    Issue number5
    Early online date22 Feb 2024
    DOIs
    Publication statusPublished - Mar 2024

    Funding

    This project has received funding from the EU Seventh Framework Programme for research, technological development and demonstration under grant agreement number 260576. The authors wish to thank the children and adolescents who took part in the study, and their families. MP.

    FundersFunder number
    Seventh Framework Programme260576

      Keywords

      • ADHD
      • long-term safety
      • methylphenidate
      • pharmacovigilance
      • sleep problems

      Fingerprint

      Dive into the research topics of 'Methylphenidate and Sleep Difficulties in Children and Adolescents With ADHD: Results From the 2-Year Naturalistic Pharmacovigilance ADDUCE Study'. Together they form a unique fingerprint.

      Cite this